Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company focused on leveraging RNA medicine to restore protein expression, recently announced the granting of stock options as part of an employment inducement strategy. On September 15, 2025, the company issued stock options to purchase a total of 135,300 shares of common stock to five new employees, in accordance with Nasdaq Listing Rule 5635(c)(4). This move is intended to attract talent to the organization as it advances its innovative research.

The granted stock options come with an exercise price of $23.40 per share, which reflects the closing price of Stoke’s common stock on the date of the grant. These options will vest over a four-year period, with one-quarter of the stocks vesting on the one-year anniversary of the vesting commencement date. The remaining shares will continue to vest monthly for the subsequent three years, contingent on the employees maintaining their positions at Stoke.

Stoke Therapeutics is currently developing its lead investigational therapy, zorevunersen, as a potential first-in-class treatment for Dravet syndrome, a severe genetic epilepsy. The company employs a proprietary methodology known as TANGO (Targeted Augmentation of Nuclear Gene Output) to create antisense oligonucleotides (ASOs) intended to restore naturally occurring protein levels. Initially focusing on central nervous system and eye diseases related to haploinsufficiency, Stoke is also exploring broader applicability of its technology across various organs and systems.

With its headquarters in Bedford, Massachusetts, Stoke Therapeutics continues to strive toward innovative solutions in the biotechnology landscape, working to address critical unmet medical needs. For further details on the company and its developments, visit their website.

Stoke Therapeutics, Inc. (Nasdaq: STOK) is making strategic moves that warrant attention from investors. The company recently announced the grant of stock options to five new employees as an inducement under Nasdaq Listing Rule 5635(c)(4). This decision comes in light of Stoke’s development of zorevunersen, a promising candidate for treating Dravet syndrome, which represents a key advance in RNA medicine aimed at restoring protein expression.

By granting 135,300 stock options with an exercise price of $23.40 per share, equivalent to its closing stock price on the grant date, Stoke is positioning itself to attract talent while aligning employee performance with shareholder interests. This approach can foster a culture of commitment, as the options will vest over four years, rewarding both retention and performance.

From a market perspective, Stoke’s strategic focus on rare diseases, particularly Dravet syndrome, alongside its proprietary TANGO technology, highlights its potential for substantial growth. The Phase 3 study of zorevunersen could be a critical inflection point, and positive results may lead to increased investor confidence and stock demand.

Investors should monitor upcoming clinical trial results closely, as successful data could fuel a bullish trend in share prices. However, caution is advised; biotech firms have inherent volatility, and unpredictable regulatory outcomes can lead to stock fluctuations. Keeping abreast of clinical trial disclosures, market reception, and emerging competitive dynamics in RNA medicine will be key for potential investors.

In conclusion, Stoke Therapeutics presents an intriguing investment opportunity, given its innovative approach and robust pipeline. Actively assessing the operational milestones and market responses will be critical in determining strategic entries or exits in STOK shares.